Higher levels of SOX11 in DCIS.com cells led to increased metastatic burden to the brain in xenograft studies (Oliemuller et al., 2020), whereas in our current study, lower levels of Sox11 led to shortened tumour latency and increased metastatic burden, particularly to the liver. This evidence concerns the gene SOX11 and ductal breast carcinoma in situ.